Scott Whitaker, the CEO of the industry lobby AvaMed, told the Senate Finance Committee that he fears tariffs will only raise the cost of care and put patients at risk if companies are unable to overcome supply chain disruptions.
Citing sources familiar with the matter, the Wall Street Journal reports that UnitedHealth Group is being investigated for criminal fraud, likely stemming from its Medicare Advantage billing practices.
The unwanted spam calls were associated with Optum's home healthcare service. Plaintiffs alleged they received the marketing calls despite opting out and never signing up, in violation of federal consumer protection laws. The company does not admit to wrongdoing.
As 2024 winds down and the number of FDA-approved medical devices packing AI approaches 1,000—the agency had the tally at 950 as of August—the industry finds itself at a “critical inflection point.”
The groups are urging the Supreme Court to uphold a lower court ruling in Garland v. VanDerStok that permits the ATF to regulate firearms made from part kits.
The agency has received an increasing number of complaints from patients enrolled in a low-value health plan without their knowledge. If finalized, a new rule would empower CMS to ban brokers from the ACA marketplace.
Two weeks ago, the FTC launched a similar antitrust suit. The pharmacy benefit managers and pharmaceutical companies are accused of artificially raising drug costs through rebates and kickbacks.
More than 40 U.S. healthcare organizations are urging Congress not to make sweeping Medicaid cuts that could result in approximately 7.6 million Americans losing health insurance.
If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.
